Dr Supriya Raj
Dr Supriya Raj
Details
Role
Team Leader/Senior Research Coordinator
Research area
Genomic Medicine
Group
Molecular Therapies
Supriya is a Senior research co-ordinator and Team leader of the Molecular Therapies group at the Murdoch Children’s Research Institute.
Following her initial training as a dentist, she completed a Master of Public Health and pivoted into the world of research. She has worked at the Melbourne Children's campus for over 20 years and is passionate about bringing meaningful changes to children’s lives.
She works with Prof Ravi Savarirayan and was an integral part of the global trials that brought Vosoritide, the very first therapy for the most common form of short stature, Achondroplasia, to market.
Supriya currently leads the group’s research program and manages over 25 clinical trials in rare paediatric bone disorders.
Following her initial training as a dentist, she completed a Master of Public Health and pivoted into the world of research. She has worked at the Melbourne Children's campus for over 20 years and is passionate about bringing meaningful changes to children’s lives.
She works with Prof Ravi Savarirayan and was an integral part of the global trials that brought Vosoritide, the very first therapy for the most common form of short stature, Achondroplasia, to market.
Supriya currently leads the group’s research program and manages over 25 clinical trials in rare paediatric bone disorders.
Supriya is a Senior research co-ordinator and Team leader of the Molecular Therapies group at the Murdoch Children’s Research Institute.
Following her initial training as a dentist, she completed a Master of Public Health and pivoted into the...
Following her initial training as a dentist, she completed a Master of Public Health and pivoted into the...
Supriya is a Senior research co-ordinator and Team leader of the Molecular Therapies group at the Murdoch Children’s Research Institute.
Following her initial training as a dentist, she completed a Master of Public Health and pivoted into the world of research. She has worked at the Melbourne Children's campus for over 20 years and is passionate about bringing meaningful changes to children’s lives.
She works with Prof Ravi Savarirayan and was an integral part of the global trials that brought Vosoritide, the very first therapy for the most common form of short stature, Achondroplasia, to market.
Supriya currently leads the group’s research program and manages over 25 clinical trials in rare paediatric bone disorders.
Following her initial training as a dentist, she completed a Master of Public Health and pivoted into the world of research. She has worked at the Melbourne Children's campus for over 20 years and is passionate about bringing meaningful changes to children’s lives.
She works with Prof Ravi Savarirayan and was an integral part of the global trials that brought Vosoritide, the very first therapy for the most common form of short stature, Achondroplasia, to market.
Supriya currently leads the group’s research program and manages over 25 clinical trials in rare paediatric bone disorders.
Top Publications
- Billich, N, Ledang, JK, Bredahl, A-M, Raj, S, Velvin, G, Ireland, PJ, Tuohy, M, Fredwall, SO, Savarirayan, R. Feeding, Nutrition, and Physical Activity From the Perspectives of People With Skeletal Dysplasia in Australia and Norway: A Mixed Qualitative Methods Study.. Am J Med Genet A 200(3) : 695 -705 2026 view publication
- Buciek, LH, Jacobsen, JR, Raj, S, Adams, A-M, Vandeleur, M, Hove, HB, Buchwald, CV, Kiaer, EK, Griffiths, A, Savarirayan, R. Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review.. Arch Dis Child 111(1) : 43 -48 2025 view publication
- Billich, N, Ledang, JK, Raj, S, Fredwall, SO, Tuohy, M, Ireland, P, Savarirayan, R. SUN-745 "We Live in an Average Height World": Perspectives of People with Short Stature Skeletal Dysplasia on Nutrition, Weight and Physical Movement.. Journal of the Endocrine Society 9(Supplement_1) : bvaf149.695 2025 view publication
- Savarirayan, R, De Bergua, JM, Arundel, P, Salles, JP, Saraff, V, Delgado, B, Leiva-Gea, A, McDevitt, H, Nicolino, M, Rossi, M, et al. Oral Infigratinib Therapy in Children with Achondroplasia.. N Engl J Med 392(9) : 865 -874 2025 view publication
- Savarirayan, R, Muslimova, E, Bergua, J, Arundel, P, Salles, J, Saraff, V, Delgado, B, Leiva-Gea, A, McDevitt, H, Nicolino, M, et al. O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study. Genetics in Medicine Open 3: 102089 2025 view publication
Page 1 of 3
Share //
